<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04906733</url>
  </required_header>
  <id_info>
    <org_study_id>D1med-ZL01</org_study_id>
    <nct_id>NCT04906733</nct_id>
  </id_info>
  <brief_title>Cetuximab Sensitivity Correlation Between Patient-Derived Organoids and Clinical Response in Colon Cancer Patients.</brief_title>
  <official_title>Patient-derived Organoids of RAS/RAF Wild-type Metastatic Right Colon Cancer to Test the Sensitivity and Clinical Consistency of Combined Treatment of Cetuximab.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>D1 Medical Technology (Shanghai) Co., Ltd, China</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>D1 Medical Technology (Shanghai) Co., Ltd, China</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Eighty patients with RAS/RAF wild-type metastatic right colon cancer will be enrolled and&#xD;
      undergo a fresh biopsy of tumor lesion before the standard treatment of chemotherapy. The&#xD;
      investigators will establish organoids from the pre-treatment biopsies. Organoids will be&#xD;
      exposed to the chemotherapy drugs or chemotherapy drugs combined with cetuximab used for each&#xD;
      patient. The sensitivity of chemotherapy drugs or combined cetuximab will be tested in the&#xD;
      organoids model. Chemotherapy strategies including 5-fluorouracil only, irinotecan only,&#xD;
      oxaliplatin only, FOLFOX, and FOLFIRI. The purpose of this study is to evaluate the&#xD;
      consistency and accuracy of a Patient-Derived Organoid (PDO) model of colon cancer to predict&#xD;
      the clinical efficacy of combined treatment of cetuximab, which to formulate the best therapy&#xD;
      regimen for each given patient.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Investigators hypothesize that the cetuximab sensitivity test results on patient-derived&#xD;
      organoids can be used to predict the treatment selection of patients with RAS/RAF wild-type&#xD;
      metastatic right colon cancer.&#xD;
&#xD;
      Objectives&#xD;
&#xD;
        1. To assess the effective rate of cetuximab target therapy on RAS/RAF wild-type right&#xD;
           colon cancer&#xD;
&#xD;
        2. To assess the consistency of organoid chemotherapy sensitivity and clinical chemotherapy&#xD;
           efficacy&#xD;
&#xD;
        3. To assess the consistency of organoid cetuximab sensitivity and clinical cetuximab&#xD;
           efficacy&#xD;
&#xD;
      The following points will be addressed:&#xD;
&#xD;
        1. The biopsy tissue of RAS/RAF wild-type metastatic right colon cancer will be collected&#xD;
           and subject to ex vivo 3-D culture to establish patient-derived tumor organoids, which&#xD;
           will be used for the drug sensitivity test.&#xD;
&#xD;
        2. Enrolled patients will treat with chemotherapy or chemotherapy combined target therapy.&#xD;
           The medication regime and treatment cycle will be decided based on the clinical&#xD;
           guideline and evidence-based medicine.&#xD;
&#xD;
        3. The patient-derived organoid-based drug sensitivity test will compare with clinical&#xD;
           treatment data of chemotherapy or chemotherapy combined target therapy, followed by&#xD;
           correlation analysis.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 15, 2021</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">June 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Correlation of ex vivo sensitivity test on patient-derived organoid models with clinical outcomes</measure>
    <time_frame>2021.05-2023.05</time_frame>
    <description>The drug sensitivity tests on patient-derived tumor organoids will compare with the clinical response of the chemo- or targeted therapy treatment. The correlation of organoids sensitivity and patient response will be evaluated.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Colon Cancer</condition>
  <condition>Organoids</condition>
  <condition>Metastatic Cancer</condition>
  <arm_group>
    <arm_group_label>Cancer patient</arm_group_label>
    <description>RAS/RAF wild-type metastatic right colon cancer patients receiving chemotherapy or chemotherapy combined target therapy treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Tumor biopsy</intervention_name>
    <description>Patients with RAS/RAF wild-type metastatic right colon cancer will receive biopsy before the standard treatment of chemotherapy or target therapy.</description>
    <arm_group_label>Cancer patient</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Tumor samples of biopsy tissue from enrolled RAS/RAF wild-type metastatic right colon cancer&#xD;
      patients are to be collected and subject to organoid isolation followed by the ex vivo drug&#xD;
      sensitivity test.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        The Department of Colorectal Surgery in Fudan University Cancer Hospital is one of the&#xD;
        largest colorectal cancer diagnosis and treatment centers in China. In 2019, more than&#xD;
        1,000 cases of recurrent and metastatic colorectal cancer were diagnosed and treated. It is&#xD;
        sufficient to obtain samples for this study from patients diagnosed and treated in this&#xD;
        department.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age from 18 to 70 years old, no gender limit&#xD;
&#xD;
          2. The primary tumor is located in the right colon, including the ileocecal area,&#xD;
             ascending colon, liver flexure, and the right part of the transverse colon.&#xD;
&#xD;
          3. Pathologically proved primary intestinal tumor with simultaneous / metachronous&#xD;
             metastasis&#xD;
&#xD;
          4. Molecular pathology confirmed as RAS/RAF wild type&#xD;
&#xD;
          5. Can tolerate and cooperate with the completion of chemotherapy and targeted therapy&#xD;
&#xD;
          6. Tissues can be obtained through puncture or colonoscopy for organoid culture&#xD;
&#xD;
          7. Complete clinical data, as well as efficacy evaluation data, can be obtained&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Less than 18 years of age or more than 70 years of age&#xD;
&#xD;
          2. The primary tumor is located in the left colon or rectum&#xD;
&#xD;
          3. Pathology results can't confirm as colon cancer&#xD;
&#xD;
          4. RAS and RAF are mutant confirmed by molecular pathology&#xD;
&#xD;
          5. Refuse to cooperate and complete the treatment, or there is a contraindication for&#xD;
             chemotherapy or targeted therapy&#xD;
&#xD;
          6. No available metastatic lesions tissue&#xD;
&#xD;
          7. Unable to obtain complete clinical data or efficacy evaluation data&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Junjie Peng, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fudan University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hanqing Lin, Dr.</last_name>
    <phone>+8615921348040</phone>
    <email>linhq@d1med.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Chunyan Cheng, Dr.</last_name>
    <phone>+8613916290275</phone>
    <email>chengcy@d1med.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Fudan University Shanghai Cancer Center</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Junjie Peng, Dr.</last_name>
      <phone>+8602164175590</phone>
      <email>pengjj67@hotmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>May 27, 2021</study_first_submitted>
  <study_first_submitted_qc>May 27, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 28, 2021</study_first_posted>
  <last_update_submitted>August 11, 2021</last_update_submitted>
  <last_update_submitted_qc>August 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colonic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>April 1, 2021</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/33/NCT04906733/ICF_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

